BRPI0417759A - combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso - Google Patents

combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso

Info

Publication number
BRPI0417759A
BRPI0417759A BRPI0417759-2A BRPI0417759A BRPI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A BR PI0417759 A BRPI0417759 A BR PI0417759A
Authority
BR
Brazil
Prior art keywords
methyl
pyrimidine
pyridyl
amine
combination
Prior art date
Application number
BRPI0417759-2A
Other languages
English (en)
Inventor
Tim H Bruemmendorf
Stefan Balabanov
Ulrike Hartmann
Winfried Kammer
Alfred Nordheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417759A publication Critical patent/BRPI0417759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçãO DE (A) N-{5-¢4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO!-2-METIL FENIL)-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA E (B) PELO MENOS UM INIBIDOR DE HIPUSINAçãO E O SEU USO". A presente invenção refere-se a um método de tratamento de um animal de sangue quente, especialmente um ser humano, tendo uma doença prolifertiva compreendendo administra ao animal uma combinação que compreende (a) N-{5-¢4-(4-metil-piperazino-metil)-benzoilamido!-2-metilfenil}-4-(3-piridil )-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação, a uma combinação compreendendo (a) e (b) como definido acima e opcionalmente pelo menos um veículo farmaceuticamente aceitável para o uso simultâneo, separado ou seqüencial, em particular para o atraso de progressão ou tratamento de uma doença proliferativa e finalmente para o uso de pelo menos um inibidor de hipusinação para a preparação de um medicamento para o atraso de progressão ou tratamento de leucemia, particularmente leucemia resistente a Imatinib.
BRPI0417759-2A 2003-12-19 2004-12-17 combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso BRPI0417759A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (en) 2003-12-19 2004-12-17 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
BRPI0417759A true BRPI0417759A (pt) 2007-04-10

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417759-2A BRPI0417759A (pt) 2003-12-19 2004-12-17 combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso

Country Status (17)

Country Link
US (1) US20080139480A1 (pt)
EP (1) EP1696917A1 (pt)
JP (1) JP2007514699A (pt)
KR (1) KR20060125810A (pt)
CN (1) CN1889952A (pt)
AU (2) AU2004298761A1 (pt)
BR (1) BRPI0417759A (pt)
CA (1) CA2547196A1 (pt)
EC (1) ECSP066656A (pt)
IL (1) IL176070A0 (pt)
MA (1) MA28240A1 (pt)
MX (1) MXPA06006925A (pt)
NO (1) NO20063326L (pt)
RU (1) RU2006125741A (pt)
TN (1) TNSN06182A1 (pt)
WO (1) WO2005058320A1 (pt)
ZA (1) ZA200603904B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2197440T3 (pl) 2007-08-31 2013-05-31 Janssen Pharmaceutica Nv Kombinacje imazalilu i hydroksypirydonów
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
US8575187B2 (en) 2008-02-06 2013-11-05 Janssen Pharmaceutica, Nv Combinations of anilinopyrimidines and pyrion compounds
CA2711762C (en) 2008-02-06 2016-11-01 Jan Pieter Hendrik Bosselaers Combinations of phenylpyrroles and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
AU2011261501B2 (en) * 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
AU2011263720B2 (en) 2010-06-10 2013-11-07 Janssen Pharmaceutica Nv Combinations of pyrimethanil and monoterpenes
WO2012001028A1 (en) 2010-07-01 2012-01-05 Janssen Pharmaceutica Nv Antimicrobial combinations of pyrion compounds with polyethyleneimines
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
DK1379257T3 (da) * 2001-03-23 2009-12-14 Enzon Inc Anticancer-profarmakon anvendende substituerede aromatiske syrer
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Also Published As

Publication number Publication date
AU2004298761A1 (en) 2005-06-30
JP2007514699A (ja) 2007-06-07
AU2009201694A1 (en) 2009-05-28
TNSN06182A1 (en) 2007-11-15
CA2547196A1 (en) 2005-06-30
NO20063326L (no) 2006-09-19
US20080139480A1 (en) 2008-06-12
KR20060125810A (ko) 2006-12-06
MXPA06006925A (es) 2006-08-23
CN1889952A (zh) 2007-01-03
RU2006125741A (ru) 2008-01-27
ZA200603904B (en) 2007-09-26
WO2005058320A1 (en) 2005-06-30
IL176070A0 (en) 2006-10-05
MA28240A1 (fr) 2006-10-02
ECSP066656A (es) 2006-10-25
EP1696917A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
BR0209647A (pt) Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
TR200000060T2 (tr) Bir N-fenil-2-pirimidinamin türevinin kristal modifikasyonu ve yapım işlemleri ve kullanımı.
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ECSP045240A (es) Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil)-benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
IL297305B1 (en) 5-membered modified heteroaryl carboxamide compounds, pharmaceutical compositions comprising the compounds, and compounds and pharmaceutical compositions for use in the treatment of hepatitis B (HBV) infection.
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
TNSN06182A1 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
JP2006505582A5 (pt)
BR0307286A (pt) Tratamento de artrite reumatóide usando imatinib
DE60235499D1 (de) ZELLWACHSTUMSHEMMER MIT ANTI-PepT-ANTIKÖRPER
DE602006015994D1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ECSP045161A (es) Piperidin-2,6-diona sustituida con heterociclo en la posición 3
JP2005508846A5 (pt)
UA6151U (en) Method for treating experimental burns
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.